MeMed BV
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —
Host-response blood test distinguishing bacterial from viral infection in fifteen minutes.
MeMed BV combines three host-response biomarkers with machine learning into a single bacterial-versus-viral score from serum or venous whole blood, delivering actionable results in about fifteen minutes for suspected acute infection.
Physicians use the score to guide antibiotic and admission decisions and support sepsis management, validated across multinational studies enrolling nearly twenty thousand patients.
| Attribute | MeMed BV | TriVerity | |
|---|---|---|---|
| Provider | |||
| Founded | — | 2016 | |
| Sells To | — | B2B, Enterprise | |
| Pricing Model | — | Product Sales, Recurring, Software | |
| Ownership | — | Venture-backed |
Provider 
Founded —
Sells To —
Pricing Model —
Ownership —
Provider 
Founded 2016
Sells To B2B, Enterprise
Pricing Model Product Sales, Recurring, Software
Ownership Venture-backed

Host-response blood test that quantifies sepsis likelihood from immune RNA in about an hour.

Instrument-free fingerstick test separating bacterial from non-bacterial infection in ten minutes.


Rapid host-response blood test that stratifies sepsis risk in emergency departments within about eight minutes.


Day Zero Diagnostics offers a sequencing-based test identifying bloodstream pathogens and resistance markers directly from whole blood without culture.

Host-response blood test that quantifies sepsis likelihood from immune RNA in about an hour.

Instrument-free fingerstick test separating bacterial from non-bacterial infection in ten minutes.
Rapid host-response blood test that stratifies sepsis risk in emergency departments within about eight minutes.

Day Zero Diagnostics offers a sequencing-based test identifying bloodstream pathogens and resistance markers directly from whole blood without culture.

Point-of-care isothermal molecular platform delivering infectious-disease results in minutes.
